abstract |
The invention discloses an antibody targeting NY-ESO-1 T cell receptors combined with anti-PD1 expression. It consists of NY‑ESO‑1 TCR α chain, P2A, NY‑ESO‑1 TCR β chain, T2A, human IL2 signal peptide, heavy and light chain variable regions of anti-human PD1 monoclonal antibody (aPD1 scFv) in series. The T cell receptor is used to modify human T lymphocytes, and the modified T cells (TCR-T cells) can be used for the treatment of positive tumors expressing HLA-A2+NY-ESO-1. The NY-ESO-1-aPD1 TCR-T cells prepared by the present invention have strong functions on specific tumor cells (U266, T2-NY-ESO-1), CD107a expression and IFNγ secretion are higher, and the effect-to-target ratio is 5 :1 in the case of U266 killing efficiency of 85%. |